ALEXIS T MASON

Allopathic & Osteopathic Physicians|Family Medicine TUSCALOOSA, AL NPI 1801152178

General Payments — all program years on this page

$1,615.50

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 84
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $288.19 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $288.1918

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Acerta Pharma LLC $105.766
ABBVIE INC. $48.583
Amgen Inc. $29.372
Lilly USA, LLC $29.032
Otsuka America Pharmaceutical, Inc. $17.041
Novo Nordisk AS $16.051
Lundbeck LLC $15.261
Exact Sciences Corporation $14.031
ITI, Inc. $13.071

By program year

Program yearAmountRecords
2018 $172.144
2019 $139.018
2020 $390.3018
2021 $229.9615
2022 $161.219
2023 $234.6912
2024 $288.1918

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1097707012 Novo Nordisk Inc $16.05 04/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104237563 AstraZeneca Pharmaceuticals LP $19.44 04/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104480932 AstraZeneca Pharmaceuticals LP $14.72 03/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104654221 AstraZeneca Pharmaceuticals LP $21.62 10/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104979557 ABBVIE INC. $16.65 02/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104979559 ABBVIE INC. $13.51 02/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104979561 ABBVIE INC. $18.42 05/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105628051 AstraZeneca Pharmaceuticals LP $16.69 04/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105775478 AstraZeneca Pharmaceuticals LP $16.60 10/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105819481 AstraZeneca Pharmaceuticals LP $16.69 07/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111645633 Amgen Inc. $14.15 07/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114560261 Exact Sciences Corporation $14.03 10/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117320564 Amgen Inc. $15.22 07/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118937218 Otsuka America Pharmaceutical, Inc. $17.04 10/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136014452 Lilly USA, LLC $15.65 01/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136022752 Lilly USA, LLC $13.38 07/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143272258 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $13.07 12/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1145943614 Lundbeck LLC $15.26 04/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.